Develops novel therapies for urological disorders and conditions affecting the urinary tract.
Unicycive Therapeutics, Inc. is a dynamic biotechnology company focused on pioneering treatments for kidney diseases across the United States. Established in 2016 and headquartered in Los Altos, California, the company is dedicated to advancing innovative therapies that address critical medical needs in nephrology. Specializing in novel drug development, Unicycive Therapeutics, Inc. aims to significantly impact patient outcomes through its groundbreaking research initiatives.
At the forefront of its pipeline is Renazorb, a promising therapeutic candidate designed for the management of hyperphosphatemia in patients suffering from chronic kidney disease. This innovative treatment approach underscores Unicycive Therapeutics, Inc.'s commitment to tackling complex renal conditions with targeted solutions. Additionally, the company is advancing UNI 494, aimed at addressing acute kidney injury, further expanding its portfolio of potential treatments for diverse kidney-related disorders.
Driven by a mission to transform kidney care through scientific innovation, Unicycive Therapeutics, Inc. leverages cutting-edge biotechnological advancements to improve the lives of patients worldwide. With a robust pipeline and a strategic focus on unmet medical needs in nephrology, the company continues to pave the way for new therapeutic options that offer hope and efficacy in the realm of kidney disease management.